Immugenin clinical and immunological effects in patients with chronic obstructive lung disease

Yanchanka U.V., Aliakhnovich N.S., Smirnova A.U., Velichinskaya O.G., Novicau D.K.

Vitebsk State Medical University, Vitebsk, Belarus

Randomized single-blind placebo-controlled prospective study of immugenin (L-lysyl-L-glutamic acid) clinical and immunological effects in parallel groups of patients treated with standard protocols of chronic obstructive pulmonary disease (COPD) was performed. Immugenin reduced the number of exacerbations and the number of acute respiratory infections in patients with COPD. Immugenin administration was safe, led to increased serum levels of immunoglobulin A during treatment and normalized initially elevated levels of immunoglobulin G after the treatment completion. Introduction immugenin led to serum TNF-a increasing, and IL-10 decreasing, in contrast to introducing a placebo.